JP2022511390A5 - - Google Patents

Info

Publication number
JP2022511390A5
JP2022511390A5 JP2021517768A JP2021517768A JP2022511390A5 JP 2022511390 A5 JP2022511390 A5 JP 2022511390A5 JP 2021517768 A JP2021517768 A JP 2021517768A JP 2021517768 A JP2021517768 A JP 2021517768A JP 2022511390 A5 JP2022511390 A5 JP 2022511390A5
Authority
JP
Japan
Prior art keywords
polypeptide
peptide
amino acid
residue
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062198 external-priority patent/WO2020106708A1/en
Publication of JP2022511390A publication Critical patent/JP2022511390A/ja
Publication of JP2022511390A5 publication Critical patent/JP2022511390A5/ja
Priority to JP2024175673A priority Critical patent/JP2025013348A/ja
Pending legal-status Critical Current

Links

JP2021517768A 2018-11-20 2019-11-19 分割インターロイキン模倣体およびその使用 Pending JP2022511390A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024175673A JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770152P 2018-11-20 2018-11-20
US62/770,152 2018-11-20
PCT/US2019/062198 WO2020106708A1 (en) 2018-11-20 2019-11-19 Split interleukin mimetics and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024175673A Division JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Publications (2)

Publication Number Publication Date
JP2022511390A JP2022511390A (ja) 2022-01-31
JP2022511390A5 true JP2022511390A5 (https=) 2022-11-24

Family

ID=69500815

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517768A Pending JP2022511390A (ja) 2018-11-20 2019-11-19 分割インターロイキン模倣体およびその使用
JP2024175673A Pending JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024175673A Pending JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Country Status (13)

Country Link
US (2) US12234572B2 (https=)
EP (1) EP3883956A1 (https=)
JP (2) JP2022511390A (https=)
KR (1) KR20210094531A (https=)
CN (2) CN112912388A (https=)
AU (1) AU2019384523B2 (https=)
BR (1) BR112021008985A2 (https=)
CA (1) CA3119472A1 (https=)
EA (1) EA202190593A1 (https=)
IL (1) IL283217A (https=)
MX (1) MX2021005593A (https=)
SG (1) SG11202103045SA (https=)
WO (1) WO2020106708A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20210025522A (ko) * 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP2022511390A (ja) 2018-11-20 2022-01-31 ユニバーシティ オブ ワシントン 分割インターロイキン模倣体およびその使用
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3210492A1 (en) * 2021-02-05 2022-08-11 Dharmacon, Inc. Fusion proteins for crispr-based transcriptional repression
WO2023044318A2 (en) * 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AU2023208426A1 (en) * 2022-01-24 2024-07-25 Novimmune Sa Composition and methods for the selective activation of cytokine signaling pathways
AU2024233726A1 (en) 2023-03-07 2025-08-21 Chugai Seiyaku Kabushiki Kaisha Conditionally activated receptor signaling by using scaffold protein
EP4722235A1 (en) * 2023-05-24 2026-04-08 Nantong Yichen Biopharma. Co. Ltd. Polypeptide, and conjugate and use thereof
IL325764A (en) * 2023-07-13 2026-03-01 Outpace Bio Inc Designed compositions of interleukin-2 cytokine and methods of use
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof
WO2026039791A1 (en) * 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026078029A1 (en) * 2024-10-10 2026-04-16 F. Hoffmann-La Roche Ag Splitted interleukin-2 prodrugs and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015080A (en) 1908-04-17 1912-01-16 George I Rockwood Apparatus for operating alarms or other devices.
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
GB0019638D0 (en) * 2000-08-09 2000-09-27 European Molecular Biology Lab Embl Peptide mimetics
WO2002101629A1 (en) * 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
SG10202110182PA (en) 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof
KR20210025522A (ko) 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
JP2022511390A (ja) 2018-11-20 2022-01-31 ユニバーシティ オブ ワシントン 分割インターロイキン模倣体およびその使用
US20220000921A1 (en) 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
US20220370563A1 (en) 2019-10-25 2022-11-24 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists
AU2020414355A1 (en) 2019-12-24 2022-08-11 Neoleukin Therapeutics, Inc. Combination therapy using an IL-2 receptor agonist and an immune checkpoint inhibitor
CN111040981A (zh) 2019-12-26 2020-04-21 南昌大学 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法
US20230340071A1 (en) 2020-03-16 2023-10-26 Neoleukin Therapeutics, Inc. Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides

Similar Documents

Publication Publication Date Title
JP2022511390A5 (https=)
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2017529067A5 (https=)
JP2023506452A5 (https=)
JP2023504914A5 (https=)
Buckland et al. Expression of measles virus nucleoprotein in Escherichia coli: use of deletion mutants to locate the antigenic sites
RU2014120536A (ru) Белки специфического связывания и их применения
JP2021505156A5 (https=)
JP2019531093A5 (https=)
JP2023123649A5 (https=)
JP2018519296A5 (https=)
JP2013534812A5 (https=)
JP2018515085A (ja) 抗がん融合ポリペプチド
JP2010535032A5 (https=)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
CN107849147A (zh) 基于二泛素突变蛋白的Her2 结合蛋白
JP2023553697A5 (https=)
JP2024509904A5 (https=)
JP2024521405A5 (https=)
JP2002514418A5 (https=)
JP2022544785A5 (https=)
JP2019505565A5 (https=)
JP2025137512A (ja) 新規に設計された共局在化依存性タンパク質スイッチを使用する超特異的細胞標的化
JP2024508969A5 (https=)
CN116075524A (zh) 转铁蛋白受体结合蛋白